Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of non-small cell lung cancer (NSCLC), either used in monotherapy or in combination with chemotherapy. While some patients achieve durable responses, some will not get benefit from this treatment. Early identification of...
Main Authors: | Yolanda Lage Alfranca, María Eugenia Olmedo Garcia, Ana Gómez Rueda, Pablo Álvarez Ballesteros, Diana Rosero Rodríguez, Marisa Torres Velasco |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/11/3245 |
Similar Items
-
Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
by: Zhu W, et al.
Published: (2023-09-01) -
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
by: Hao Sun, et al.
Published: (2020-10-01) -
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
by: Andrea De Giglio, et al.
Published: (2020-09-01) -
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
by: Courèche Kaderbhaï, et al.
Published: (2019-02-01) -
Obesity paradox in patients with non‐small cell lung cancer undergoing immune checkpoint inhibitor therapy
by: Ji Hyun Lee, et al.
Published: (2023-12-01)